Journal Club Recap: January 11, 2019

Wednesday, January 16, 2019

January 11, 2019: At Journal Club, our experts sat down to discuss a paper on Epstein Barr Virus (EBV) specific T cell therapy for patients with progressive MS.

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis

Researchers were able to use patient blood samples to produce cytotoxic T cells that specifically target cells infected with EBV, a virus found in almost all patients with MS. Many people have inactive EBV infections, but activation of the virus is linked with a predisposition for MS. This study found that 7/10 patients receiving the treatment demonstrated neurological improvement. No serious adverse effects were reported, but further investigation is required to determine the clinical efficacy of this treatment.

News Archive

Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy

 

Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.